Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells $777,939.25 in Stock

Posted by Stuart Ham on Oct 24th, 2025

Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report) major shareholder Reprogrammed Interchange Llc sold 25,717 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $30.25, for a total value of $777,939.25. Following the completion of the transaction, the insider owned 1,178,725 shares of the company’s stock, valued at $35,656,431.25. This represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

On Tuesday, October 21st, Reprogrammed Interchange Llc sold 200 shares of Vor Biopharma stock. The shares were sold at an average price of $30.07, for a total value of $6,014.00.
On Monday, October 20th, Reprogrammed Interchange Llc sold 11,616 shares of Vor Biopharma stock. The shares were sold at an average price of $30.05, for a total value of $349,060.80.
On Thursday, October 16th, Reprogrammed Interchange Llc sold 2,021 shares of Vor Biopharma stock. The stock was sold at an average price of $30.45, for a total value of $61,539.45.
On Wednesday, October 15th, Reprogrammed Interchange Llc sold 71,655 shares of Vor Biopharma stock. The stock was sold at an average price of $31.92, for a total value of $2,287,227.60.
On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The stock was sold at an average price of $30.32, for a total value of $1,020,813.76.
On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The stock was sold at an average price of $32.44, for a total value of $713,874.64.
On Friday, October 10th, Reprogrammed Interchange Llc sold 40,983 shares of Vor Biopharma stock. The stock was sold at an average price of $30.97, for a total value of $1,269,243.51.
On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total value of $1,567,709.88.
On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The stock was sold at an average price of $33.87, for a total value of $2,549,123.94.
On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total value of $934,796.16.

Vor Biopharma Stock Up 4.8%

Shares of VOR opened at $27.76 on Friday. Vor Biopharma Inc. has a 1 year low of $2.62 and a 1 year high of $65.80. The company has a market capitalization of $190.16 million, a P/E ratio of -0.10 and a beta of 2.07. The business’s 50-day moving average is $35.72.

Vor Biopharma (NASDAQ:VOR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

Wall Street Analysts Forecast Growth

VOR has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a report on Wednesday, September 24th. Baird R W upgraded Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Vor Biopharma in a research note on Thursday, August 14th. Finally, Wall Street Zen cut Vor Biopharma to a “strong sell” rating in a research note on Saturday, June 28th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Vor Biopharma has an average rating of “Hold” and an average target price of $77.83.

View Our Latest Stock Analysis on Vor Biopharma

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. OMERS ADMINISTRATION Corp purchased a new position in shares of Vor Biopharma during the first quarter valued at approximately $100,000. Goldman Sachs Group Inc. boosted its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares during the last quarter. Money Concepts Capital Corp boosted its position in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after buying an additional 26,535 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Vor Biopharma during the first quarter valued at approximately $140,000. Finally, XTX Topco Ltd purchased a new position in shares of Vor Biopharma during the second quarter valued at approximately $66,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.